Tags

Type your tag names separated by a space and hit enter

Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Int Psychogeriatr 2014; 26(4):543-54IP

Abstract

BACKGROUND

The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not.

METHODS

Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging.

RESULTS

The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 AD patients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%.

CONCLUSION

There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline.

Authors+Show Affiliations

Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia.National Ageing Research Institute (NARI), Parkville, Victoria, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Macquarie University, Sydney, NSW, Australia.Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia.Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia.Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.CogState Limited, Melbourne, Victoria, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia.Latrobe University, Melbourne, Victoria, Australia.Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.Macquarie University, Sydney, NSW, Australia.Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia.Austin Health, Aged Care, Heidelberg, Victoria, Australia.Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia.Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia.Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24252258

Citation

Ellis, Kathryn A., et al. "Rates of Diagnostic Transition and Cognitive Change at 18-month Follow-up Among 1,112 Participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL)." International Psychogeriatrics, vol. 26, no. 4, 2014, pp. 543-54.
Ellis KA, Szoeke C, Bush AI, et al. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr. 2014;26(4):543-54.
Ellis, K. A., Szoeke, C., Bush, A. I., Darby, D., Graham, P. L., Lautenschlager, N. T., ... Ames, D. (2014). Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics, 26(4), pp. 543-54. doi:10.1017/S1041610213001956.
Ellis KA, et al. Rates of Diagnostic Transition and Cognitive Change at 18-month Follow-up Among 1,112 Participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr. 2014;26(4):543-54. PubMed PMID: 24252258.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). AU - Ellis,Kathryn A, AU - Szoeke,Cassandra, AU - Bush,Ashley I, AU - Darby,David, AU - Graham,Petra L, AU - Lautenschlager,Nicola T, AU - Macaulay,S Lance, AU - Martins,Ralph N, AU - Maruff,Paul, AU - Masters,Colin L, AU - McBride,Simon J, AU - Pike,Kerryn E, AU - Rainey-Smith,Stephanie R, AU - Rembach,Alan, AU - Robertson,Joanne, AU - Rowe,Christopher C, AU - Savage,Greg, AU - Villemagne,Victor L, AU - Woodward,Michael, AU - Wilson,William, AU - Zhang,Ping, AU - Ames,David, AU - ,, Y1 - 2013/11/20/ PY - 2013/11/21/entrez PY - 2013/11/21/pubmed PY - 2015/1/6/medline SP - 543 EP - 54 JF - International psychogeriatrics JO - Int Psychogeriatr VL - 26 IS - 4 N2 - BACKGROUND: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not. METHODS: Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging. RESULTS: The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 AD patients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%. CONCLUSION: There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline. SN - 1741-203X UR - https://www.unboundmedicine.com/medline/citation/24252258/Rates_of_diagnostic_transition_and_cognitive_change_at_18_month_follow_up_among_1112_participants_in_the_Australian_Imaging_Biomarkers_and_Lifestyle_Flagship_Study_of_Ageing__AIBL__ L2 - https://www.cambridge.org/core/product/identifier/S1041610213001956/type/journal_article DB - PRIME DP - Unbound Medicine ER -